PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q1 2018 13F Holders as of 31 Mar 2018

Type / Class
Equity / COM
Total 13F shares
64,277,556
Share change
+3,391,340
Total reported value
$478,078,878
Put/Call ratio
92%
Price per share
$7.46
Number of holders
144
Value change
+$26,255,802
Number of buys
80
Number of sells
56

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q1 2018

As of 31 Mar 2018, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 144 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 64,277,556 shares. The largest 10 holders included FEDERATED INVESTORS INC /PA/, BlackRock Inc., EAGLE ASSET MANAGEMENT INC, VANGUARD GROUP INC, CARILLON TOWER ADVISERS, INC., STATE STREET CORP, ARMISTICE CAPITAL, LLC, BAKER BROS. ADVISORS LP, ARDSLEY ADVISORY PARTNERS, and PINNACLE ASSOCIATES LTD. This page lists 144 institutional shareholders reporting positions in this security for the Q1 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.